2/13/2024

Dexrazoxane Hydrochloride Injection

Products Affected - Description

- Dexrazoxane injection, Eugia US, 250 mg, vial, 1 count, NDC 55150-0434-01
- Dexrazoxane injection, Eugia US, 500 mg, vial, 1 count, NDC 55150-0437-01
- Dexrazoxane injection, Fosun Pharma, 250 mg, vial, 1 count, NDC 72266-0235-01
- Dexrazoxane injection, Fosun Pharma, 500 mg, vial, 1 count, NDC 72266-0101-01

Reason for the Shortage

- Eugia did not provide a reason for the shortage.
- Breckenridge discontinued dexrazoxane injection in September 2023.
- Fosun did not provide a reason for the shortage.
- Hikma has dexrazoxane injection available.
- Information regarding Almaject product availability is forthcoming.

Available Products

- Dexrazoxane injection, Hikma, 250 mg, vial, 1 count, NDC 00143-9247-01
- Dexrazoxane injection, Hikma, 500 mg, vial, 1 count, NDC 00143-9248-01

Estimated Resupply Dates

- Eugia has dexrazoxane 250 mg and 500 mg vials on intermittent back order and the company is releasing supplies as they become available.
- Fosun has dexrazoxane 250 mg and 500 mg vials on back order and the company cannot estimate a release date.

Updated

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.